No biomarker
|
Leiomyosarcoma
|
No biomarker
|
Leiomyosarcoma
|
trabectedin Sensitive: A1 - Approval
|
trabectedin Sensitive: A1 - Approval
|
No biomarker
|
Leiomyosarcoma
|
No biomarker
|
Leiomyosarcoma
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
No biomarker
|
Leiomyosarcoma
|
No biomarker
|
Leiomyosarcoma
|
doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Leiomyosarcoma
|
No biomarker
|
Leiomyosarcoma
|
PTC596 Sensitive: B - Late Trials
|
PTC596 Sensitive: B - Late Trials
|
Chr amplification(4)(q22.1)
|
Leiomyosarcoma
|
Chr amplification(4)(q22.1)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr del(3)(q14.2)
|
Leiomyosarcoma
|
Chr del(3)(q14.2)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr del(11)(q25)
|
Leiomyosarcoma
|
Chr del(11)(q25)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr del(2)(q14.1)
|
Leiomyosarcoma
|
Chr del(2)(q14.1)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr del(2)(p12)
|
Leiomyosarcoma
|
Chr del(2)(p12)
|
Leiomyosarcoma
|
eribulin mesylate Sensitive: C3 – Early Trials
|
eribulin mesylate Sensitive: C3 – Early Trials
|
Chr del(1)(q44)
|
Leiomyosarcoma
|
Chr del(1)(q44)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr amplification(8)(q13.2)
|
Leiomyosarcoma
|
Chr amplification(8)(q13.2)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr amplification(8)(q22.2)
|
Leiomyosarcoma
|
Chr amplification(8)(q22.2)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr amplification(13)(q13.3)
|
Leiomyosarcoma
|
Chr amplification(13)(q13.3)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr amplification(20)(p12.2)
|
Leiomyosarcoma
|
Chr amplification(20)(p12.2)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
Chr amplification(4)(q26)
|
Leiomyosarcoma
|
Chr amplification(4)(q26)
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
ATRX mutation
|
Leiomyosarcoma
|
ATRX mutation
|
Leiomyosarcoma
|
eribulin mesylate Resistant: C3 – Early Trials
|
eribulin mesylate Resistant: C3 – Early Trials
|
TP53 mutation
|
Leiomyosarcoma
|
TP53 mutation
|
Leiomyosarcoma
|
eribulin mesylate Sensitive: C3 – Early Trials
|
eribulin mesylate Sensitive: C3 – Early Trials
|
ATRX mutation
|
Leiomyosarcoma
|
ATRX mutation
|
Leiomyosarcoma
|
dacarbazine Resistant: C3 – Early Trials
|
dacarbazine Resistant: C3 – Early Trials
|
TP53 mutation
|
Leiomyosarcoma
|
TP53 mutation
|
Leiomyosarcoma
|
dacarbazine Resistant: C3 – Early Trials
|
dacarbazine Resistant: C3 – Early Trials
|
AKT1 mutation + mTOR mutation
|
Leiomyosarcoma
|
AKT1 mutation + mTOR mutation
|
Leiomyosarcoma
|
CB-228 Sensitive: C3 – Early Trials
|
CB-228 Sensitive: C3 – Early Trials
|
TMB-H
|
Leiomyosarcoma
|
TMB-H
|
Leiomyosarcoma
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
MYH9-ALK + ALK-WDR43
|
Leiomyosarcoma
|
MYH9-ALK + ALK-WDR43
|
Leiomyosarcoma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
PTEN mutation + TSC1 mutation
|
Leiomyosarcoma
|
PTEN mutation + TSC1 mutation
|
Leiomyosarcoma
|
CB-228 Sensitive: C4 – Case Studies
|
CB-228 Sensitive: C4 – Case Studies
|
NF1 mutation
|
Leiomyosarcoma
|
NF1 mutation
|
Leiomyosarcoma
|
IPN60090 Sensitive: C4 – Case Studies
|
IPN60090 Sensitive: C4 – Case Studies
|
YWHAE-JAZF1 fusion
|
Leiomyosarcoma
|
YWHAE-JAZF1 fusion
|
Leiomyosarcoma
|
regorafenib Sensitive: C4 – Case Studies
|
regorafenib Sensitive: C4 – Case Studies
|
PLK4 expression
|
Leiomyosarcoma
|
PLK4 expression
|
Leiomyosarcoma
|
CFI-400945 Sensitive: D – Preclinical
|
CFI-400945 Sensitive: D – Preclinical
|
CSPG4 overexpression
|
Leiomyosarcoma
|
CSPG4 overexpression
|
Leiomyosarcoma
|
CSPG4.TNK Sensitive: D – Preclinical
|
CSPG4.TNK Sensitive: D – Preclinical
|
HAT1 overexpression
|
Leiomyosarcoma
|
HAT1 overexpression
|
Leiomyosarcoma
|
pazopanib Resistant: D – Preclinical
|
pazopanib Resistant: D – Preclinical
|
MAN1A1-ROS1 rearrangement
|
Leiomyosarcoma
|
MAN1A1-ROS1 rearrangement
|
Leiomyosarcoma
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|
TP53 mutation
|
Leiomyosarcoma
|
TP53 mutation
|
Leiomyosarcoma
|
selinexor + eribulin mesylate Sensitive: D – Preclinical
|
selinexor + eribulin mesylate Sensitive: D – Preclinical
|